Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 1, 2009, Pages 103-114

  Nowak Göttl, Ulrike ^a   Kenet, Gili ^b   Mitchell, Lesley G ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b SHEBA MEDICAL CENTER   (Israel)

^c STOLLERY CHILDREN S HOSPITAL   (Canada)

Author keywords

antithrombin; asparaginase; central venous line; LMWH; prednisone; stroke; thrombophilia; venous thromboembolism

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PREDNISONE; UROKINASE; VINCRISTINE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CENTRAL VENOUS CATHETER; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; ECHOGRAPHY; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; ONSET AGE; PATHOGENESIS; PHLEBOGRAPHY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOPHILIA; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; RISK FACTORS; VENOUS THROMBOEMBOLISM; VINCRISTINE;

EID: 61649096620     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.01.003     Document Type: Review

References (93)

1. Andrew M., David M., Adams M., et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 83 (1994) 1251-1257
2. Van Ommen C.H., Heijboer H., Büller H.R., et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 139 (2001) 676-681
3. Goldenberg N.A., Knapp-Clevenger R., and Manco-Johnson M.J. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 351 (2004) 1081-1088
4. Kuhle S., Koloshuk B., Marzinotto V., et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res 111 (2003) 227-233
5. Monagle P., Adams M., Mahoney M., et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 47 (2000) 763-766
6. Kuhle S., Massicotte P., Chan A., et al. Systemic thromboembolism in children. Data from the 1-800-NO-CLOTS Consultation Service. Thromb Haemost 92 (2004) 722-728
7. Athale U., Siciliano S., Thabane L., et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 51 (2008) 792-797
8. Bajzar L., Chan A.K., Massicotte M.P., et al. Thrombosis in children with malignancy. Curr Opin Pediatr 18 (2006) 1-9
9. Caruso V., Iacoviello L., Di C.A., et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 108 (2006) 2216-2222
10. Payne J.H., and Vora A.J. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 138 (2007) 430-445
11. Appel I.M., Hop W.C., and Pieters R. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases. Blood Coagul Fibrinolysis 17 (2006) 139-146
12. Carlsson H., Stockelberg D., Tengborn L., et al. Effects of Erwinia-asparaginase on the coagulation system. Eur J Haematol 55 (1995) 289-293
13. Castaman G., Rodeghiero F., and Dini E. Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia. Haematologica 75 (1990) 567-569
14. Eckhof-Donovan S., Schwamborn D., Körholz D., et al. Thrombosis in children with acute lymphoblastic leukemia treated with the COALL protocol. Klin Padiatr 206 (1994) 327-330
15. Eden O.B., Shaw M.P., Lilleyman J.S., et al. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol 18 (1990) 497-502
16. Farinasso L., Bertorello N., Garbarini L., et al. Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study. Leukemia 21 (2007) 552-556
17. Hongo T., Okada S., Ohzeki T., et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int 44 (2002) 293-299
18. Jaime-Perez J.C., and Gomez-Almaguer D. The complex nature of the prothrombotic state in acute lymphoblastic leukemia of childhood. Haematologica 88 (2003) ELT25
19. Kirschke R., Nürnberger W., Eckhof-Donovan S., et al. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol. Klin Padiatr 210 (1998) 285-290
20. Korte W., Feldges A., Baumgartner C., et al. Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report. Klin Padiatr 206 (1994) 331-333
21. Kucuk O., Kwaan H.C., Gunnar W., et al. Thromboembolic complications associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 55 (1985) 702-706
22. Legnani C., Palareti G., Pession A., et al. Intravascular coagulation phenomena associated with prevalent fall in fibrinogen and plasminogen during L-asparaginase treatment in leukemic children. Haemostasis 18 (1988) 179-186
23. Mauz-Körholz C., Junker R., Göbel U., et al. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 83 (2000) 840-843
24. Miniero R., Pastore G., Saracco P., et al. Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Am J Pediatr Hematol Oncol 8 (1986) 116-120
25. Mitchell L.G., Halton J.M., Vegh P.A., et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol 16 (1994) 120-126
26. Mitchell L.G., Andrew M., Hanna K., et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 97 (2003) 508-516
27. Nowak-Göttl U., Funk M., Mosch G., et al. Univariate tolerance regions for fibrinogen, antithrombin III, protein C, protein S, plasminogen and alpha 2-antiplasmin in children using the new Automated Coagulation Laboratory (ACL) method. Klin Padiatr 206 (1994) 437-439
28. Nowak-Göttl U., Boos J., and Wolff E. Influence of two different asparaginase preparations on coagulation and fibrinolysis: a randomised trial. Fibrinolysis 8 (1994) S66-S68
29. Nowak-Göttl U., Strater R., Dübbers A., et al. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene. Blood Coagul Fibrinolysis 7 (1996) 684-688
30. Nowak-Göttl U., Ahlke E., Schulze-Westhoff P., et al. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haematol 95 (1996) 123-126
31. Nowak-Göttl U., Werber G., Ziemann D., et al. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica 81 (1996) 127-131
32. Nowak-Göttl U., Ahlke E., Klösel K., et al. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations. Eur J Pediatr 156 (1997) 848-850
33. Nowak-Göttl U., Sträter R., Heinecke A., et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 94 (1999) 3678-3682
34. Nowak-Göttl U., Wermes C., Junker R., et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 93 (1999) 1595-1599
35. Nowak-Göttl U., Kotthoff S., Hagemeyer E., et al. Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease. a prospective study. Thromb Res 103 (2001) 93-101
36. Pastore G., Miniero R., Saracco P., et al. Thrombosis and hemorrhage during L-asparaginase therapy. J Pediatr 102 (1983) 639-640
37. Priest J.R., Ramsay N.K., Latchaw R.E., et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 46 (1980) 1548-1554
38. Priest J.R., Ramsay N.K., Bennett A.J., et al. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr 100 (1982) 990-995
39. Priest J.R., Ramsay N.K., Steinherz P.G., et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 100 (1982) 984-989
40. Pui C.H., Jackson C.W., Chesney C.M., et al. Involvement of von Willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. Am J Hematol 25 (1987) 291-298
41. Risseeuw-Appel I.M., Dekker I., Hop W.C., et al. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study. Med Pediatr Oncol 23 (1994) 335-343
42. Semeraro N., Montemurro P., Giordano P., et al. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia. Thromb Haemost 64 (1990) 38-40
43. Shapiro A.D., Clarke S.L., Christian J.M., et al. Thrombosis in children receiving L-asparaginase. Determining patients at risk. Am J Pediatr Hematol Oncol 15 (1993) 400-405
44. Sutor A.H., Mall V., and Thomas K.B. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. Klin Padiatr 211 (1999) 201-204
45. Uszynski M., Osinska M., Zekanowska E., et al. Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes. Med Sci Monit 6 (2000) 108-111
46. Zaunschirm A., and Muntean W. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 3 (1986) 19-25
47. O'Meara A., Daly M., and Hallinan F.H. Increased antithrombin concentration in children with acute lymphoblastic leukemia receiving L-asparaginase therapy. Med Pediatr Oncol 16 (1988) 169-174
48. Nowak-Göttl U., Heinecke A., von Kries R., et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 103 (2001) 165-172
49. Ruud E., Holmstrom H., de Lange C., et al. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study. Pediatr Hematol Oncol 23 (2006) 207-216
50. Kaste S.C., Gronemeyer S.A., Hoffer F.A., et al. Pilot study of noninvasive detection of venous occlusions from central venous access devices in children treated for acute lymphoblastic leukemia. Pediatr Radiol 29 (1999) 570-574
51. Kuhle S., Spavour M., Massicotte-Nolan P., et al. Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost 6 (2008) 589-594
52. Molloy W., English J., O'Dwyer R., et al. Clinical findings in the diagnosis of proximal deep vein thrombosis. Ir Med J 75 (1982) 119-120
53. Male C., Chait P., Ginsberg J.S., et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 87 (2002) 593-598
54. Male C., Kuhle S., and Mitchell L. Diagnosis of venous thromboembolism in children. Semin Thromb Hemost 29 (2003) 377-390
55. Kenet G., Kirkham F., Niederstadt T., et al. Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol 6 (2007) 595-603
56. Kieslich M., Porto L., Lanfermann H., et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 25 (2003) 484-487
57. Mitchell L., Hoogendoorn H., Giles A.R., et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood 83 (1994) 386-391
58. Mitchell L., Andrew M., Hanna K., et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 90 (2003) 235-244
59. Santoro N., Giordano P., Del Vecchio G.C., et al. Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study. J Pediatr Hematol Oncol 27 (2005) 153-157
60. Glaser D.W., Medeiros D., Rollins N., et al. Catheter-related thrombosis in children with cancer. J Pediatr 138 (2001) 255-259
61. McLean T.W., Fisher C.J., Snively B.M., et al. Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. J Clin Oncol 23 (2005) 3024-3029
62. Young G., Albisetti M., Bonduel M., et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation 118 (2008) 1373-1382
63. Elhasid R., Lanir N., Sharon R., et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 12 (2001) 367-370
64. Nowak-Göttl U., Ahlke E., Fleischhack G., et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 101 (2003) 2529-2533
65. Sifontes M.T., Nuss R., Hunger S.P., et al. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 96 (1997) 484-489
66. Wermes C., von Depka P.M., Lichtinghagen R., et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 158 Suppl. 3 (1999) S143-S146
67. Arico M., Gamba G., Raiteri E., et al. Clotting abnormalities in children during maintenance chemotherapy for acute lymphoblastic leukemia. Haematologica 76 (1991) 472-474
68. de Stefano V., Gugliotta L., Mazzucconi M.G., et al. Hypercoagulability during induction therapy of acute lymphoblastic leukemia is of scarce clinical relevance. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto. Blood 81 (1993) 2468-2469
69. Homans A.C., Rybak M.E., Baglini R.L., et al. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol 5 (1987) 811-817
70. Oner A.F., Gürgey A., Kirazli S., et al. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leuk Lymphoma 33 (1999) 361-364
71. Pitney W.R., Phadke K.P., and Dean S. Antithrombin III deficiency during asparaginase therapy. Lancet 1 (1980) 493-494
72. Ramsay N.K., Coccia P.F., Krivit W., et al. The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia. Cancer 40 (1977) 1398-1401
73. Solano C., Lopez J., Gomez N., et al. Acute lymphoblastic leukemia: hypofibrinogenemia with a low incidence of clinical complications is often found during induction remission therapy. Blood 80 (1992) 1366-1368
74. Capizzi R., and Holcenberg J.S. L-asparaginase. In: Holland J., and Frei E. (Eds). Cancer Medicine (1992), Lea & Freibiger, Philadelphia 796-803
75. Boos J., Nowak-Göttl U., Jurgens H., et al. Loss of activity of Erwinia asparaginase on repeat applications. J Clin Oncol 13 (1995) 2474-2475
76. Ohnuma T., Holland J.F., Freeman A., et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 30 (1970) 2297-2305
77. Boos J., Werber G., Ahlke E., et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 32A (1996) 1544-1550
78. Duval M., Suciu S., Ferster A., et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 99 (2002) 2734-2739
79. Dentali F., Gianni M., Agnelli G., et al. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 6 (2008) 70-75
80. Giordano P., Santoro N., Del Vecchio G.C., et al. T-immunophenotype is associated with an increased prevalence of thrombosis in children with acute lymphoblastic leukemia. A retrospective study. Haematologica 88 (2003) 1079-1080
81. Goldenberg N.A. Long-term outcomes of venous thrombosis in children. Curr Opin Hematol 12 (2005) 370-376
82. Journeycake J.M., Eshelman D., and Buchanan G.R. Post-thrombotic syndrome is uncommon in childhood cancer survivors. J Pediatr 148 (2006) 275-277
83. Korte W., and Greiner J. PARKAA paves the way. Thromb Haemost 90 (2003) 163-164
84. Randolph A.G., Cook D.J., Gonzales C.A., et al. Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest 113 (1998) 165-171
85. Dillon P.W., Jones G.R., Bagnall-Reeb H.A., et al. Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study. J Clin Oncol 22 (2004) 2718-2723
86. Halton J.M., Mitchell L.G., Vegh P., et al. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am J Hematol 47 (1994) 157-161
87. Nowak-Göttl U., Rath B., Binder M., et al. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica 80 (1995) 451-453
88. Nowak-Göttl U., Kuhn N., Wolff J.E., et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol 56 (1996) 35-38
89. Ruud E., Holmstrom H., De Lange C., et al. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies - a randomized, controlled study. Acta Paediatr 95 (2006) 1053-1059
90. Meister B., Kropshofer G., Klein-Franke A., et al. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 50 (2008) 298-303
91. Monagle P., Chalmers E., Chan A., et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 Suppl. (2008) 887S-968S
92. Pui C.H., Chesney C.M., Weed J., et al. Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. J Clin Oncol 3 (1985) 1266-1272
93. Athale U.H., Siciliano S.A., Crowther M., et al. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 129 (2005) 803-810